Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.62 |
| ▸ | LMNA | P02545 | 6/20 | 0.62 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.57 |
| ▸ | MEN1 | O00255 | 8/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | STAT3 | P40763 | 5/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3421633 | 0.89 | ALDH1A1 (0.62) | MAPTLMNAGAAALDH1A1MEN1 | |
| SCHEMBL3919729 | 0.89 | ALDH1A1 (0.65) | MAPTLMNAGAAALDH1A1MEN1 | |
| SCHEMBL3920972 | 0.88 | MEN1 (0.70) | MAPTLMNAGAAALDH1A1MEN1 | |
| SCHEMBL3931598 | 0.86 | MAPT (0.69) | MAPTLMNAGAAALDH1A1MEN1 | |
| SCHEMBL3931603 | 0.85 | MAPT (0.68) | MAPTLMNAGAAALDH1A1MEN1 | |
| SCHEMBL3419640 | 0.85 | MAPT (0.79) | MAPTLMNAALDH1A1MEN1KMT2A | |
| SCHEMBL3351788 | 0.85 | STAT3 (0.46) | MAPTLMNAGAAALDH1A1MEN1 | |
| SCHEMBL13166094 | 0.85 | STAT3 (0.46) | MAPTLMNAGAAALDH1A1MEN1 | |
| SCHEMBL3419045 | 0.85 | MEN1 (0.54) | MEN1KMT2ASTAT3L3MBTL1GRM1 | |
| SCHEMBL28453179 | 0.84 | STAT3 (0.68) | MAPTLMNAALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163538-A1 | Tetrahydropyridothiophenes For Use In The Treatment Of Cancer | PEKARI KLAUS | 2009-06-25 | — | — | US | disclosed |
| US-20090163538-A1 | Tetrahydropyridothiophenes For Use In The Treatment Of Cancer | PEKARI KLAUS | 2009-06-25 | — | — | US | disclosed |
| US-20090163538-A1 | Tetrahydropyridothiophenes For Use In The Treatment Of Cancer | PEKARI KLAUS | 2009-06-25 | — | — | US | disclosed |
| US-7517986-B2 | Tetrahydropyridothiophenes for use in the treatment of cancer | 4SC AG (DE) | 2009-04-14 | — | — | US | disclosed |
| US-7517986-B2 | Tetrahydropyridothiophenes for use in the treatment of cancer | 4SC AG (DE) | 2009-04-14 | — | — | US | disclosed |
| US-7517986-B2 | Tetrahydropyridothiophenes for use in the treatment of cancer | 4SC AG (DE) | 2009-04-14 | — | — | US | disclosed |
| EP-1756118-B1 | TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER | NYCOMED GMBH (DE) | 2008-05-28 | — | — | EP | disclosed |
| EP-1756118-B1 | TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER | NYCOMED GMBH (DE) | 2008-05-28 | — | — | EP | disclosed |
| US-20070213360-A1 | Tetrahydropyridothiophenes for Use in the Treatment of Cancer | NYCOMED GMBH (DE) | 2007-09-13 | — | — | US | disclosed |
| US-20070213360-A1 | Tetrahydropyridothiophenes for Use in the Treatment of Cancer | NYCOMED GMBH (DE) | 2007-09-13 | — | — | US | disclosed |
| US-20070213360-A1 | Tetrahydropyridothiophenes for Use in the Treatment of Cancer | NYCOMED GMBH (DE) | 2007-09-13 | — | — | US | disclosed |
| EP-1756118-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER | Altana Pharma AG (DE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005118592-A1 | TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER | ALTANA PHARMA AG (DE) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163538-A1 | Tetrahydropyridothiophenes For Use In The Treatment Of Cancer | BCL2, BAX, MCL1 | MAPT 1411/4885LMNA 3962/4885GAA 3779/4885 |
| US-20070213360-A1 | Tetrahydropyridothiophenes for Use in the Treatment of Cancer | BCL2, BAX, MCL1 | MAPT 1402/4885LMNA 3882/4885GAA 3762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.